

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

NCT05723198

Status	RECRUITING
Phase	Phase 3
Sponsor	Eli Lilly and Company
Enrollment	595 participants

Key Eligibility Criteria

Inclusion (9)

- Enrollment will be fully sequential by age group, with adolescents (12 to less than 18 years old) enrolling before children (6 to less than 12 years old).
- Have severe areata alopecia (AA) for at least 1 year
- Diagnosis for at least 1 year
- Current AA episode of at least 6 months' duration
- SALT score \geq 50% at screening and baseline
- ... and 4 more (see full listing online)

Exclusion (9)

- Primarily "diffuse" type of AA (characterized by diffuse hair shedding).
- Are currently experiencing other forms of alopecia including, but not limited to trichotillomania, telogen effluvium, chemotherapy-induced hair loss, or any other concomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis) that would interfere with evaluations of the effect of study medication on AA.
- Are largely or wholly incapacitated permitting little or no self-care, such as being bedridden
- Have uncontrolled arterial hypertension
- Have had major surgery within 8 weeks prior to screening or will require major surgery during the study
- ... and 4 more (see full listing online)

Locations (127 total)

Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States
University of Alabama at Birmingham, Birmingham, Alabama, United States
Investigate MD, Scottsdale, Arizona, United States
... and 124 more locations